Holen Sie sich die Stockscreener-App
10.95
4.89%
0.51
Handel nachbörslich:
10.95
Carlsmed Inc Aktie (CARL) Neueste Nachrichten
CARL Maintains Buy Rating -- Price Target Lowered to $18.00 by T - GuruFocus
Carlsmed (NASDAQ:CARL) Price Target Cut to $18.00 by Analysts at Truist Financial - MarketBeat
Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026 - The Manila Times
Top Carlsmed (CARL) Competitors 2026 - MarketBeat
Carlsmed Showcases Personalized Spine Fusion Gains, Cervical Expansion and Medicare Tailwinds at Needham Conf - Yahoo Finance
The Goldman Sachs Group Has Lowered Expectations for Carlsmed (NASDAQ:CARL) Stock Price - Defense World
Carlsmed (CARL) Analyst Rating: Goldman Sachs Lowers Price Targe - GuruFocus
Carlsmed (NASDAQ:CARL) Price Target Lowered to $17.00 at The Goldman Sachs Group - MarketBeat
CARL.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CARL.O PE Ratio & Valuation, Is CARL.O Overvalued - Intellectia AI
CARL Technical Analysis & Stock Price Forecast - Intellectia AI
CARL News & Events - Intellectia AI
CARL.O Technical Analysis & Stock Price Forecast - Intellectia AI
Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference - Bitget
Carlsmed (NASDAQ:CARL) Upgraded at Zacks Research - Defense World
Carlsmed (NASDAQ:CARL) Upgraded by Zacks Research to Hold Rating - MarketBeat
Carlsmed, Inc. (NASDAQ:CARL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Carlsmed reports Q4, FY 2025 revenue above estimate - MSN
Carlsmed, Inc.: Fundamental Analysis and Financial Ratings | I82 | US14280C1053 - marketscreener.com
Carlsmed Poised for Positive Growth Trajectory - San Diego Business Journal
Stryker, THINK Surgical and Carlsmed Named Winners of 2026 OMTEC® Excellence Awards - The Providence Journal
Carlsmed joins Russell 2000 Index following Q3 IPO - MSN
Head-To-Head Comparison: Carlsmed (CARL) vs. Its Rivals - Defense World
Comparing Carlsmed (CARL) & The Competition - Defense World
Head to Head Review: Carlsmed (CARL) and The Competition - Defense World
Carlsmed Earnings Call Highlights Rapid Growth, Rising Costs - TipRanks
Carlsmed Stock Down 6% Since IPO But Goldman Bullish And Predicts 35% Upside Potential — Retail Traders Stay Bearish - MSN
Carlsmed (CARL) versus The Competition Head to Head Analysis - Defense World
Carlsmed unveils custom cervical plating tech - MSN
Carlsmed (CARL) vs. Its Peers Financial Survey - Defense World
Carlsmed Unveils Personalized Spine Platform, Targets $70M-$75.5M 2025 Revenue at Conference - Defense World
Contrasting Carlsmed (CARL) & Its Peers - Defense World
Carlsmed (CARL) vs. Its Competitors Head-To-Head Contrast - Defense World
Carlsmed (CARL) versus The Competition Financial Contrast - Defense World
CARLSMED CEO Michael Cordonnier Sells Shares - TradingView
Contrasting Carlsmed (CARL) & Its Rivals - Defense World
CARL: Personalized spine surgery platform posts 86% annual growth and expands into cervical market - TradingView
CARL: Personalized spine surgery platform drives rapid growth, clinical success, and strong reimbursement - TradingView
Carlsmed (CARL) vs. Its Rivals Critical Survey - Defense World
Brokerages Set Carlsmed, Inc. (NASDAQ:CARL) Target Price at $21.33 - Defense World
Carlsmed (CARL) versus Its Peers Financial Contrast - Defense World
Carlsmed (NASDAQ:CARL) Cut to “Strong Sell” at Zacks Research - Defense World
Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS), Wave Life Sciences (WVE) and Carlsmed, Inc. (CARL) - The Globe and Mail
Carlsmed, Inc. (NASDAQ:CARL) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Carlsmed (NASDAQ:CARL) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
Head to Head Survey: Carlsmed (CARL) versus Its Competitors - Defense World
Carlsmed (CARL) Revenue Growth At 85.9% Tests Bearish Profitability Narratives - simplywall.st
Carlsmed Q4 2025 revenue up 61% to USD 15.2M - Medical Buyer
Carlsmed Q4 Earnings Call Highlights - MarketBeat
Carlsmed, Inc. Reports Strong Q4 2025 Earnings and Growth Outlook - Intellectia AI
Carlsmed Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Carlsmed Inc (NASDAQ:CARL) Reports Q4 Revenue Beat and Narrower-Than-Expected Loss - ChartMill
Earnings call transcript: Carlsmed reports strong revenue, stock dips Q4 2025 - Investing.com
Carlsmed (NASDAQ:CARL) Issues Quarterly Earnings Results - MarketBeat
1.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):